Advances in the efficacy and safety of scleral collagen cross-linking in the prevention and treatment of pathologic myopia
10.3980/j.issn.1672-5123.2023.12.16
- VernacularTitle:巩膜胶原交联防治病理性近视有效性及安全性的研究进展
- Author:
Wen-Chao LYU
1
,
2
;
Tian LIANG
1
,
2
;
Li-Na WANG
1
,
2
;
Chun-Ni YAN
1
,
2
;
Yuan-Yuan CHAO
1
,
2
;
Jin-Xin SONG
1
,
2
Author Information
1. Xi'an No.1 Hospital
2. Shaanxi Institute of Ophthalmology, Xi'an 710002, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
pathologic myopia;
sclera;
cross-linking;
genipin;
posterior scleral reinforcement
- From:
International Eye Science
2023;23(12):2021-2025
- CountryChina
- Language:Chinese
-
Abstract:
In 2004, it was the first time that Wollensak and Spoerl had applied physical and chemical cross-linking methods to scleral tissue. They found that the biomechanical strength of cross-linked sclera, induced by riboflavin/ultraviolet A, glyceraldehyde and glutaraldehyde, could be improved and proposed that scleral collagen cross-linking is expected to be a new method for the treatment of pathologic myopia. In recent years, a series of explorations have been made on the effectiveness and adverse reactions of physical and chemical cross-linking in the prevention and treatment of pathologic myopia, including the establishment of various animal models and different myopia modeling methods, the improvement of cross-linking methods, the amelioration of the measurement of biomechanical strength of scleral tissue and the attention of biological parameters such as the thickness of retinal nerve fiber layer and the amplitude of electroretinogram in vivo. Genipin-crosslinking of the scleral collagen combined with posterior scleral contraction/reinforcement has been applied to clinical research. This review summarizes physical cross-linking and the genipin-crosslinking of scleral collagen to explore the effectiveness and safety of the methods in the prevention and treatment of the pathologic myopia.
